T&I AsiaWatch for December 19th, 2022
Last week's struggle to get deals done (or to get out) is paying off. We'll end better than hoped, if well below 2021's record year. But 2023? Gonna be tough.
Editor’s Note: Hillhouse Capital buys Aussie CRO George Clinical, beating out Affinity Equity Partners. Primavera Capital delivers 30% of its intended fundraising via SPAC of Fosun Capital’s Lanvin brand. China is getting sicker and messier by the day. PE and VC transactions dwindle to nearly…